請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57026
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 張上淳 | |
dc.contributor.author | Han-Lin Chen | en |
dc.contributor.author | 陳翰霖 | zh_TW |
dc.date.accessioned | 2021-06-16T06:33:13Z | - |
dc.date.available | 2016-10-15 | |
dc.date.copyright | 2014-10-15 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-05 | |
dc.identifier.citation | 1. Blackford MG, Glover ML, Reed MD. Lower respiratory tract infections. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy: a pathophysiologic approach. 8 ed. New York: McGraw-Hill; 2011:1845-65.
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388-416. 3. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. 4. Ewig S, Welte T, Chastre J, Torres A. Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 2010;10:279-87. 5. Brito V, Niederman MS. Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Curr Opin Infect Dis 2009;22:316-25. 6. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med 2014;370:543-51. 7. The top 10 causes of death. World Health Organization, 2013. (Accessed 7/10, 2014, at http://www.who.int/mediacentre/factsheets/fs310/en/.) 8. Heron M. Deaths: leading causes for 2010. Natl Vital Stat Rep 2013;61:1-118. 9. 97年度死因統計記者會發布資料-死因統計結果分析. 衛生福利部統計處, 2009. (Accessed 12/27, 2013, at http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2281.) 10. 98年死因統計記者會~民國98年死因結果分析. 衛生福利部統計處, 2010. (Accessed 12/27, 2013, at http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2421.) 11. 99年主要死因分析. 衛生福利部統計處, 2011. (Accessed 12/27, 2013, at http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2564.) 12. 民國100年主要死因分析. 衛生福利部統計處, 2012. (Accessed 12/27, 2013, at http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2622.) 13. 民國101年主要死因分析. 衛生福利部統計處, 2013. (Accessed 12/27, 2013, at http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2747.) 14. Herrera-Lara S, Fernandez-Fabrellas E, Cervera-Juan A, Blanquer-Olivas R. Do seasonal changes and climate influence the etiology of community acquired pneumonia? Arch Bronconeumol 2013;49:140-5. 15. 重要參考指標. 內政部統計處, 2014. (Accessed 5/4, 2014, at http://www.moi.gov.tw/stat/index.aspx.) 16. 老人健康促進計畫(2009-2012). 衛生福利部國民健康署, 2009. (Accessed 5/4, 2014, at http://www.hpa.gov.tw/BHPNet/Web/HealthTopic/TopicArticle.aspx?id=201110210001&Class=2&parentid=201109300006.) 17. 肺炎臨床診療指引. 國家衛生研究院, 2007. (Accessed 6/2, 2014, at http://ebpg.nhri.org.tw/module/check.aspx?catalog=1501.) 18. Lee YT, Chen SC, Chan KC, Wu TC, Tsao SM, Chan CH. Impact of infectious etiology on the outcome of Taiwanese patients hospitalized with community acquired pneumonia. Journal of infection in developing countries 2013;7:116-24. 19. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185:1004-14. 20. 結核病診治指引(第五版). 衛生福利部疾病管制署, 2013. (Accessed 6/17, 2014, at http://www.cdc.gov.tw/professional/infectionreportinfo.aspx?treeid=56ca56252a0fa705&nowtreeid=2aa8435e1709fbfb&tid=18D9FAA6FCA5C24A.) 21. Donowitz GR. Acute Pneumonia. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell: Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 7 ed. Philadelphia, Pennsylvania: Churchill Livingstone; 2010:891-916. 22. Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002;137:791-7. 23. Muder RR. Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. Am J Med 1998;105:319-30. 24. Wu CL, Ku SC, Yang KY, et al. Antimicrobial drug-resistant microbes associated with hospitalized community-acquired and healthcare-associated pneumonia: a multi-center study in Taiwan. J Formos Med Assoc 2013;112:31-40. 25. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007;51:3568-73. 26. Carratala J, Mykietiuk A, Fernandez-Sabe N, et al. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 2007;167:1393-9. 27. Shindo Y, Sato S, Maruyama E, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest 2009;135:633-40. 28. Park HK, Song JU, Um SW, et al. Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respir Med 2010;104:1729-35. 29. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005;128:3854-62. 30. Schreiber MP, Chan CM, Shorr AF. Resistant pathogens in nonnosocomial pneumonia and respiratory failure: is it time to refine the definition of health-care-associated pneumonia? Chest 2010;137:1283-8. 31. Chalmers JD, Taylor JK, Singanayagam A, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis 2011;53:107-13. 32. Grenier C, Pepin J, Nault V, et al. Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia. J Antimicrob Chemother 2011;66:1617-24. 33. Park SC, Kang YA, Park BH, et al. Poor prediction of potentially drug-resistant pathogens using current criteria of health care-associated pneumonia. Respir Med 2012;106:1311-9. 34. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005;49:1965-72. 35. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003;37:230-7. 36. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002;113:120-6. 37. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002;346:747-50. 38. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002;35:819-24. 39. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999;29:797-800. 40. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med 2009;30:3-9. 41. File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001. 42. Infectious Diseases Society of Taiwan, Taiwan Society of Pulmonary and Critical Medicine, Medical Foundation in Memory of Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Diseases Research and Education, CY Lee's Resaerch Foundation for Pediatric Infectious Disease and Vaccines. Guidelines on antimicrobial therapy of pneumonia in adults in Taiwan, revised 2006. J Microbiol Immunol Infect 2007;40:279-83. 43. Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med 2013;188:985-95. 44. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74. 45. Pneumonia Measures. Joint Commission, 2011. (Accessed 6/7, 2014, at http://www.jointcommission.org/pneumonia/.) 46. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997;278:2080-4. 47. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44. 48. Mandell LA, Bartlett JG, Dowell SF, File TM, Jr., Musher DM, Whitney C. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003;37:1405-33. 49. Fee C, Weber EJ, Bacchetti P, Maak CA. Effect of emergency department crowding on pneumonia admission care components. Am J Manag Care 2011;17:269-78. 50. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008;168:2205-10. 51. Kaku N, Yanagihara K, Morinaga Y, et al. The definition of healthcare-associated pneumonia (HCAP) is insufficient for the medical environment in Japan: a comparison of HCAP and nursing and healthcare-associated pneumonia (NHCAP). Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2013;19:70-6. 52. Yap V, Datta D, Metersky ML. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Infect Dis Clin North Am 2013;27:1-18. 53. CDC/NHSN Surveillance Definitions for Specific Types of Infections. Centers for Disease Control and Prevention, 2013. (Accessed 12/24, 2013, at http://www.cdc.gov/nhsn/acute-care-hospital/vap/index.html.) 54. 醫療照護相關感染監測定義(譯自美國cdc2008版). 衛生福利部疾病管制署, 2013. (Accessed 12/25, 2013, at http://www.cdc.gov.tw/professional/info.aspx?treeid=beac9c103df952c4&nowtreeid=29e258298351d73e&tid=63DC78B180156753.) 55. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-9. 56. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006;130:11-5. 57. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-50. 58. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-82. 59. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29. 60. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-51. 61. Valles J, Calbo E, Anoro E, et al. Bloodstream infections in adults: importance of healthcare-associated infections. J Infect 2008;56:27-34. 62. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55. 63. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637. 64. Notice. Kidney International Supplements 2012;2:1-138. 65. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81. 66. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-7. 67. Ceftaroline Fosamil for the Treatment of Community-acquired Bacterial Pneumonia and Complicated Skin and Skin Structure Infections. U.S. Food and Drug Administration, 2010. (Accessed 2/17, 2014, at http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm224656.pdf.) 68. Yen MY, Hu BS, Chen YS, et al. A prospective etiologic study of community-acquired pneumonia in Taiwan. J Formos Med Assoc 2005;104:724-30. 69. Lauderdale TL, Chang FY, Ben RJ, et al. Etiology of community acquired pneumonia among adult patients requiring hospitalization in Taiwan. Respir Med 2005;99:1079-86. 70. Viasus D, Garcia-Vidal C, Castellote J, et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine (Baltimore) 2011;90:110-8. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/57026 | - |
dc.description.abstract | 研究背景:
肺炎是最常見的下呼道感染之一,傳統上可分類為社區型肺炎和院內型肺炎。然而由於醫療照護系統的進步,院外發生的肺炎病人可能因密切接觸或曝露於醫療照護環境中而有多重抗藥性致病菌風險;美國胸腔學會及美國感染症學會於2005年發表的治療指引將這類病人歸類為「醫療照護相關型肺炎(healthcare-associated pneumonia)」,並建議使用2到3種廣效抗生素,而與臺灣的指引有所出入。但近來研究認為醫療照護相關型肺炎病人的異質性相當高且不同國家、地區致病菌種差異相當大,因此有必要了解當地社區型肺炎與醫療照護相關型肺炎基本特性的差異、致病菌種,期待能找出適當的經驗性抗生素,尤其是在人滿為患的醫院急診部。 研究目的: 瞭解臺大醫院急診部之社區發作肺炎之特性、抗生素處方型態、致病菌種分布、治療結果,並探討治療失敗之相關因子,期待能找出臺大醫院急診社區發作肺炎病人適當的初始經驗性抗生素。 研究方法: 本研究為病歷回溯性研究,病人群為2013年1月1日至2013年12月31日至臺大醫院急診部診斷碼為肺炎之隨機抽樣所得之病人。記錄並分析此病人群中的社區型肺炎及醫療照護相關型肺炎的基本特性、醫師處方之經驗性抗生素型態、菌種分布及抗藥性情形等。以治療結束時、第30天及病人出院時之死亡率來分析治療結果。最後用羅吉斯迴歸分析找出第30天死亡之風險因子。 研究結果: 在本研究時段之一年間,臺大醫院急診部共計有2963名符合診斷碼之肺炎病人,隨機抽樣之500名病人中,171名符合納入條件並有完整之資料,其中150名為住院病人。在150名住院病人中,97名屬社區型肺炎,53名屬醫療照護相關型肺炎。醫療照護相關型肺炎病人以曾住院過佔最多數為66.0%,其次為曾於醫療院所接受過靜脈輸注之抗生素佔20.8%。醫療照護相關型肺炎病人比起社區型肺炎病人,來診時意識狀態較為不清、有較高的肺炎嚴重度、共病嚴重度及APACHE Ⅱ score。此外,醫療照護相關型肺炎病人較常有無法行走、管餵等問題、較常使用H2 blockers、PPI制酸劑;過去三個月較常使用過抗生素。但其他方面,無論在年齡、症狀及徵象、影像學上是否涉及肺之雙側等皆無統計學上顯著差異。 社區發作肺炎常以單一初始經驗性抗生素治療,約佔7成。社區型肺炎病人較常單用non-antipseudomonal β-lactams/β-lactamase inhibitors或ceftriaxone;醫療照護相關型肺炎病人則偏好用β-lactams/β-lactamase inhibitors(antipseudomonal β-lactams/β-lactamase inhibitors與non-antipseudomonal β-lactams/β-lactamase inhibitors)。而兩組皆沒有單用macrolides。至於併用抗生素方面,大多是併用macrolides,其中社區型肺炎病人最常與non-antipseudomonal β-lactams/β-lactamase inhibitors併用;醫療照護相關型肺炎病人最常與antipseudomonal β-lactams/β-lactamase inhibitors或non-antipseudomonal β-lactams/β-lactamase inhibitors併用;皆沒有併用aminoglycosides或vancomycin;但在7天內會有1.3%的病人會使用vancomycin。 以入院後一天內之檢體培養結果及血清學檢驗、尿液抗原檢驗結果分析,只有18.8%的致病菌診斷率。K. pneumoniae與P. aeruginosa為主要致病菌;而由於人數較少,不同致病菌種在社區型肺炎組或醫療照護相關型肺炎組之間並沒有統計學上顯著差異,需待未來更大型研究闡明。而抗藥性方面,菌種對於amoxicillin/clavulanate、ampicillin/sulbactam、piperacillin/tazobactam、cefotaxime、levofloxacin及ciprofloxacin的抗藥性比例介於0%至22%之間。多重抗藥性菌種佔致病菌檢驗陽性的社區發作肺炎病人13.3%。以醫療照護相關型肺炎預測多重抗藥性致病菌,其sensitivity為75.0%、specificity 73.0%;positive predictive value 30.0%、negative predictive value 95.0%。 對於社區型肺炎或醫療照護相關型肺炎的治療結果,在排除掉其他感染可能的影響後,住院天數、是否住進加護病房、加護病房天數及併發症方面皆沒有統計學上顯著差異;但在死亡率方面,無論病人出院時之死亡率或入院30天內死亡率皆以醫療照護相關型肺炎組較高。 30天內死亡之風險因子,在排除其他感染下,包含高Charlson comorbidity index以及有呼吸衰竭併發症。 結論: 醫療照護相關型肺炎之病人有較高的肺炎嚴重度、共病嚴重度、較常使用過抗生素。社區發作肺炎常以單一初始經驗性抗生素治療,但由於本研究致病菌診斷率低(18.8%)而無法清楚證實此種處方之合理性。雖然本研究為回溯性研究,K. pneumoniae、P. aeruginosa是最常見菌種且抗藥性並不高。30天內死亡之風險因子,包括高Charlson comorbidity index以及有呼吸衰竭併發症。 關鍵字: 肺炎、急診、社區發作、社區型、醫療照護相關型、經驗性抗生素 | zh_TW |
dc.description.abstract | Background:
Pneumonia is one of the most common lower respiratory tract infections and traditionally can be categorized into community-acquired pneumonia (CAP) and nosocomial pneumonia. However, because healthcare systems have progressed a lot, patients with pneumonia developing outside the hospital were likely to have multidrug-resistant pathogens due to closely contacting or exposuring to healthcare systems and had been recategorized as “healthcare-associated pneumonia (HCAP)” by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) since 2005. A recommendation on 2 to 3 broad-spectrum antibiotics combinations for treatment of HCAP patients was made by the ATS/IDSA guidelines. Nevertheless, a recent review regarded HCAP patients as a heterogeneous group and pathogens pattern varied from region/country to region/country. Therefore, to know the characteristics of local patients of CAP and HCAP and pathogen patterns better and to treat CAP and HCAP properly in Taiwan are necessary, especially in the crowded emergency department of a hospital. Objectives: The aims of this study were to describe characteristics of patients with community-onset pneumonia, who visited the emergency department (ED) of the National Taiwan University Hospital (NTUH), the antibiotic prescription patterns, the distribution of pathogens, treatment outcomes, and risk factors of treatment failure and to find the appropriate initial empirical antibiotics for the community-onset pneumonia. Methods: This is a retrospective and chart-review study, which included randomly sampled patients who visited the ED of the NTUH with pneumonia-related diagnosis from January 1st, 2013 to December 31st, 2013. Information of the patients was collected and analyzed, including characteristics of the community-onset pneumonia, prescription patterns of empirical treatment, the distribution of pathogens and resistance patterns, definite antibiotics and treatment outcomes. D30 mortality was used as the primary endpoint of treatment outcomes. The logistic regression method was used to find the prognostic factors. Results: There were 2963 pneumonia patients diagnosed at the ED of NTUH during the one year study period. 500 of them were randomly selected and 171 of them were included in the analysis after excluding those with hospital-acquired pneumonia, those with incomplete data, and those who met other exclusion criteria; 150 needed to be hospitalized. Among 150 patients who needed to be hospitalized, 97 patients were categorized as CAP and 53 patients were HCAP. Most HCAP patients were recent hospitalized, accounted for 66.0%; patients recently receiving IV antibiotics were accounted for 20.8%. HCAP patients were more likely to be admitted with an altered mental status and had higher pneumonia severity index score, comorbidity severity score and APACHE Ⅱ score compared to CAP patients. Also, HCAP patients were more likely to be unable to walk, to have tube feeding, to take H2 blockers or PPI antacids, and to have taken antibiotics within previous 3 months. However, in other aspects, there were no statistically significant differences in ages, signs and symptoms, and bilateral lung involvement by imaging techniques between the two groups of patients. Monotherapy was preferred to be used as empirical regimen for treatment of community-onset pneumonia, accounted for 70% of the patients. CAP patients were more likely to be treated with non-antipseudomonal β-lactams/β-lactamase inhibitors (39.2%) or ceftriaxone (9.3%); HCAP patients were more likely to be prescribed with β-lactams/β-lactamase inhibitors, both antipseudomonal (41.5%) and non-antipseudomonal (32.1%). No macrolide monotherapy was prescribed for community-onset pneumonia patients who need to be hospitalized. As to combination therapy, non-antipseudomonal β-lactams/β-lactamase inhibitors plus azithromycin was more commonly prescribed for CAP patients (19.6%), and antipseudomonal β-lactams/β-lactamase inhibitors plus azithromycin or non-antipseudomonal β-lactams/β-lactamase inhibitors plus azithromycin was more commonly prescribed for HCAP patients (both 5.7%). No aminoglycosides or vancomycin was used initially. But within 7 days, 1.3% of community-onset pneumonia patients would receive vancomycin treatment. Specimens for culture sampled within 1 day, serologic tests, and urine or sputum antigen tests were included for pathogens detection for the patients, and the diagnostic rate was only 18.8%. Klebsiella pneumoniae and Pseudomonas aeruginosa were the most common pathogens; no significant difference was found between CAP and HCAP patients, but further studies with larger sample size are required due to small sample size of this study. As to the susceptibility results, the rates of resistance to amoxicillin/clavulanate, ampicillin/sulbactam, piperacillin/tazobactam, cefotaxime, levofloxacin, and ciprofloxacin were around 0% to 22%. Multidrug-resistant pathogens accounted for 13.3% of community-onset pneumonia patients with positive pathogen diagnostic tests. Prediction of multidrug-resistant pathogens by any factor of HCAP had a sensitivity of 75.0%, a specificity of 73.0%; positive predictive value of 30.0% and negative predictive value of 95.0%. There were no statistically significant differences between CAP and HCAP patients in length of hospitalization, ICU admission, length of ICU hospitalization, and frequency of complications. The mortality rate of the HCAP group was higher than that of the CAP group, for both in-hospital mortality rate and 30-day mortality rate. By multivariate logistic regression analysis, the risk factors for 30-day mortality included patients who had complication of respiratory failure and high Charlson comorbidity index score when patients with other infections were excluded in the analysis. Conclusions: HCAP patients were more likely to have higher pneumonia severity index score and comorbidity severity score and to have taken antibiotics recently. Monotherapy was preferred to be used to treat community-onset pneumonia. The pathogens were detected in very low rate because aggressive diagnostic tests were used in low percentage of patients. K. pneumoniae and P. aeruginosa were the most common pathogens, and the resistance rates to various antibiotics were not high. The mortality rate was higher in the HCAP group. The risk factors for 30-day mortality included patients who had the complication of respiratory failure and high Charlson comorbidity index. Keywords: Pneumonia, emergency department, community-onset, community-acquired, healthcare-associated, empirical antibiotic | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T06:33:13Z (GMT). No. of bitstreams: 1 ntu-103-R01451002-1.pdf: 1739776 bytes, checksum: da6750d9f33ac075e292b35f3ed6cfe9 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 目錄
致謝 i 中文摘要 iii Abstract vi 目錄 ix 表目錄 xi 圖目錄 xiii 第一章 前言 1 第二章 文獻探討 2 2.1流行病學 2 2.2肺炎之診斷與分類 2 2.3致病菌種 13 2.4治療準則 16 2.5社區型肺炎及醫療照護相關型肺炎研究之處方型態 17 2.6影響治療結果之因子 20 2.7急診病人之特殊性 20 2.8醫療照護相關型肺炎之爭議處 20 第三章 研究目的 22 第四章 研究方法 23 4.1研究設計 23 4.2研究時間、地點與對象 26 4.3資料收集 27 4.4名詞定義 31 4.5治療結果評估 36 4.6統計分析 37 第5章 研究結果 38 5.1收案流程 38 5.2病人基本資料 41 5.3處方之抗生素 56 5.4致病菌 68 5.5治療結果 72 5.6風險因子分析 76 第6章 討論 80 6.1肺炎族群之基本特性 80 6.2初始經驗性抗生素處方型態 81 6.3致病菌種與抗生素感受性試驗結果 82 6.4不同方法對於抗效性菌種之預測性 83 6.5醫療照護相關型肺炎與社區型肺炎之治療結果比較 86 6.6風險因子分析 87 6.7研究限制 88 第7章 結論 90 參考文獻 92 | |
dc.language.iso | zh-TW | |
dc.title | 社區發作肺炎病人之抗生素治療分析 | zh_TW |
dc.title | A retrospective study of antibiotics treatment for patients with community-onset pneumonia | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳宜君,王振泰,林慧玲 | |
dc.subject.keyword | 肺炎,急診,社區發作,社區型,醫療照護相關型,經驗性抗生素, | zh_TW |
dc.subject.keyword | pneumonia,emergency department,community-onset,community-acquired,healthcare-associated,empirical antibiotic, | en |
dc.relation.page | 98 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-05 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 臨床藥學研究所 | zh_TW |
顯示於系所單位: | 臨床藥學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 1.7 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。